- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06942559
Stimulation synchronisée de l'oscillation cérébrale du DMPFC (BOSS-OCD)
Stimulation synchronisée de l'oscillation cérébrale du DMPFC: une étude en un seul aveugle pour la neuromodulation personnalisée dans le TOC
This trial aims to obtain initial evidence about the clinical efficacy and modulation of neurophysiological markers in obsessive compulsive disorder (OCD) using personalized (i.e., electroencephalography (EEG)-triggered) repetitive transcranial magnetic stimulation (rTMS) as compared to non-personalized (i.e., non-EEG triggered), standard rTMS applied to the dorsomedial prefrontal cortex.
Aperçu de l'étude
Statut
Description détaillée
This trial uses a prospective, randomized, single-blind study design with two treatment arms at the Centre for Addiction and Mental Health (CAMH) in Toronto, ON, Canada. The study aims to compare the clinical effects of EEG-triggered, personalized rTMS (i.e., experimental arm) in the treatment of OCD to those of non-EEG triggered, non-personalized rTMS (i.e., active-comparator arm). Additionally, the study aims to compare the modulation of neurophysiological (i.e., EEG) markers of OCD between the two arms.
Study treatment will be administered five days per week across a six-week treatment course for a total of 30 sessions. Both rTMS arms will use the same TMS coil, stimulation intensity, number of pulses, and anatomical target (i.e., dorsomedial prefrontal cortex).
Clinical outcomes will be measured using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) with clinical response defined as a ≥30% improvement on the Y-BOCS. The self-reported revised Obsessive Compulsive Inventory (OCI-R) and Clinical Global Impressions - Improvement (CGI-I) scale will also be used. Neurophysiological outcomes will be measured by the change in frontoparietal theta amplitude (i.e., 4-7 Hz) and power of TMS-induced theta oscillations.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ashley Melichercik, MSc
- Numéro de téléphone: 30899 416-535-8501
- E-mail: ashley.melichercik@camh.ca
Sauvegarde des contacts de l'étude
- Nom: Brigitte Zrenner, MD
- Numéro de téléphone: 34574 416-535-8501
- E-mail: brigitte.zrenner@camh.ca
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M6J 1H1
- Recrutement
- Centre for Addiction and Mental Health
-
Contact:
- Nina E. Bahl, MSc
- Numéro de téléphone: 30882 416-535-8501
- E-mail: nina.bahl@camh.ca
-
Chercheur principal:
- Brigitte Zrenner, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Are 18-65 years old;
- Have OCD as a primary disorder, confirmed by a MINI diagnosis of OCD;
- Have OCD with treatment resistance as defined by failure of at least a course of cognitive-behavioural therapy or a single trial (≥4 weeks) of an SSRI;
- Does not meet criteria for substance use disorder as determined by the MINI (with the exception of nicotine and caffeine);
- Have a Y-BOCS score ≥20;
- Are fluent in the English language (spoken, written and reading);
- Have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening;
- Must be deemed to have capacity to provide informed consent;
- Must sign and date the informed consent form;
- Stated willingness to comply with all study procedures.
Exclusion Criteria:
- Have any contraindications to TMS as determined by the TASS questionnaire (18);
- Have a history of a medical or neurological disorder that affects CNS (such as, traumatic brain injury, stroke, Parkinson);
- Are pregnant or breast feeding. TMS is not unsafe in pregnancy and therefore we are not requiring a pregnancy test prior to entry. If patients become pregnant during the study they will not be excluded. We are not including patients who are currently aware of being pregnant as OCD can be affected during the later stages of pregnancy and therefore is a potential confound;
- Have history of seizures;
- Have any metal implant or dentures;
- Have serious or unstable medical condition requiring immediate investigation or treatment (e.g. severe or recent cardiac disease);
- Have cardiac pacemaker, cochlear implants, implanted electronic devices or non- electronic metallic implants or other contraindications for TMS;
- Taking more than 2mg of lorazepam or equivalent benzodiazepine, or any anticonvulsant medication;
- Fulfill MINI criteria for Alcohol Use Disorder;
- Have received any ablative neurological procedure (e.g., focused ultrasound).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: RTMS personnalisé et déclenché par EEG
|
The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot. EEG data will be analyzed in real-time using the bossdevice MEDICAL and TMS pulses will be synchronized to the negative peak of the frontoparietal theta oscillation. 500 consecutive EEG theta-oscillation negative-peak triggered quadruplet bursts with a 5ms inter-pulse-interval will be applied at a median inter-burst interval of 2-3s. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 15-30 minutes.
Autres noms:
|
|
Comparateur actif: RTMS non personnalisés et non permanents
|
The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot. High-frequency rTMS consisting of 50 trains at 20 Hz (2s on, 18s off) will be delivered. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 15-30 minutes.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Délai: From screening to the end of the follow-up period (1-month post-intervention)
|
The Y-BOCS is used to (a) qualify OCD symptoms using a symptom checklist and (b) assess their severity using a symptom severity rating scale. The checklist allows the participant to identify the thoughts and behaviours that are part of their OCD. The severity scale assesses five dimensions of obsessions and compulsions: time spent or occupied, interference with functioning or relationships, degree of distress, resistance, and control (i.e., success with resistance). The scale ranges from 0-40; a lower score indicates less severe OCD, while a higher score indicates more severe OCD. |
From screening to the end of the follow-up period (1-month post-intervention)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Obsessive Compulsive Inventory - Revised (OCI-R)
Délai: From screening to the end of the follow-up period (1-month post-intervention)
|
The OCI-R is a self-reported 18-item scale that measures symptom severity across six domains of OCD: washing, checking, ordering, neutralizing, obsessing, and hoarding. The scale ranges from 0-72; lower scores indicate less severe OCD (or a subclinical presentation for scores <21), while higher scores indicate more severe OCD. |
From screening to the end of the follow-up period (1-month post-intervention)
|
|
Clinical Global Impressions - Improvement (CGI-I) Scale
Délai: From screening to the end of the follow-up period (1-month post-intervention)
|
The CGI-I is a clinician-determined assessment that rates change in global clinical presentation (i.e., improvement or worsening) from the baseline presentation on a 7-point scale. |
From screening to the end of the follow-up period (1-month post-intervention)
|
|
Electroencephalography (EEG) Markers of OCD
Délai: From screening to the end of the follow-up period (1-week post-intervention)
|
|
From screening to the end of the follow-up period (1-week post-intervention)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Brigitte Zrenner, MD, Centre for Addiction and Mental Health
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 104-2023
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified data from this project may be used for future research by internal and/or external project collaborators upon participant consent.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .